Placebo-driven clinical trials of yeast-derived ß-(1,3) glucan in children with chronic respiratory problems

Annals of Translational Medicine

Volumn 1, Issue 3, 2013, Pages

  Vetvicka, Vaclav ^a   Richter, Josef ^b   Svozil, Vladimir ^c   Dobiášová, Lucie Rajnohová ^b   Král, Vlastimil ^b  

^a University of Louisville School of Medicine   (United States)

^b Zdravotní ústav se sídlem v Ústí nad Labem   (Czech Republic)

^c Sanatorium EDEL ^*  (Czech Republic)

Author keywords

Children; Glucan; Lysozyme; Mucosal immunity; Saliva

Indexed keywords

EID: 85015484643     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2013.07.01     Document Type: Article

References (32)

1. Novak M, Vetvicka V. Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets 2009;9:67-75.
2. Hamano K, Gohra H, Katoh T, et al. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. Int J Immunopharmacol 1999;21:531-40.
3. Ross GD, Baran JT, Allendorf DJ, et al. Newly identified function for the complement (C) system in regulating hematopoiesis and bone marrow reconstitution after radiation injury. Mol Immunol 2003;40:196-7.
4. Ross GD, Vetvicka V, Yan J, et al. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 1999;42:61-74.
5. Thornton BP, Vetvicka V, Pitman M, et al. Analysis of the sugar specificity and molecular location of the beta-glucanbinding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 1996;156:1235-46.
6. Xia Y, Vetvicka V, Yan J, et al. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 1999;162:2281-90.
7. Davis JM, Murphy EA, Brown AS, et al. Effects of moderate exercise and oat beta-glucan on innate immune function and susceptibility to respiratory infection. Am J Physiol Regul Integr Comp Physiol 2004;286:R366-72.
8. Novak M, Vetvicka V. Beta-glucans, history, and the present: immunomodulatory aspects and mechanisms of action. J Immunotoxicol 2008;5:47-57.
9. Vetvicka V, Novak M. Biological action of ß-glucan. In: Vetvicka V, Novak M, eds. Biology and Chemistry of Beta Glucan. Beerensteinerhof, Bussum: Bentham Science Publishers, 2011:10-8.
10. Spector SL. The common cold: current therapy and natural history. J Allergy Clin Immunol 1995;95:1133-8.
11. Vetvicka V, Vetvickova J. ß-1,3-Glucan: Silver bullet or hot air? Open Glycoscience 2010;3:1-6.
12. Vetvicka V, Vetvickova J. Effects of glucan on immunosuppressive actions of mercury. J Med Food 2009;12:1098-104.
13. Vetvicka V, Vetvickova J. Effects of yeast-derived betaglucans on blood cholesterol and macrophage functionality. J Immunotoxicol 2009;6:30-5.
14. Yan J, Allendorf DJ, Brandley B. Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer. Expert Opin Biol Ther 2005;5:691-702.
15. Vetvicka V, Vetvickova J. Physiological effects of different types of beta-glucan. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007;151:225-31.
16. Vetvicka V, Vetvickova J. ß(1-3)-D-glucan affects adipogenesis, wound healing and inflammation. Orient Pharm Exp Med 2011;11:169-75.
17. Vetvicka V, Vetvickova J. A comparison of injected and orally administered ß-glucans. JANA 2008;11:42-8.
18. Ramberg JE, Nelson ED, Sinnott RA. Immunomodulatory dietary polysaccharides: a systematic review of the literature. Nutr J 2010;9:54.
19. Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial 2004;17:432-7.
20. Schenkels LC, Veerman EC, Nieuw Amerongen AV. Biochemical composition of human saliva in relation to other mucosal fluids. Crit Rev Oral Biol Med 1995;6:161-75.
21. Azar R, Richard A. Elevated salivary C-reactive protein levels are associated with active and passive smoking in healthy youth: A pilot study. J Inflamm (Lond) 2011;8:37.
22. Sköld CM, Blaschke E, Eklund A. Transient increases in albumin and hyaluronan in bronchoalveolar lavage fluid after quitting smoking: possible signs of reparative mechanisms. Respir Med 1996;90:523-9.
23. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004;279:48487-90.
24. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
25. Bard E, Laibe S, Bettinger D, et al. New sensitive method for the measurement of lysozyme and lactoferrin for the assessment of innate mucosal immunity. part I: timeresolved immunofluorometric assay in serum and mucosal secretions. Clin Chem Lab Med 2003;41:127-33.
26. Brown LR, Frome WJ, Wheatcroft MG, et al. The effect of Skylab on the chemical composition of saliva. J Dent Res 1977;56:1137-43.
27. Soo-Quee Koh D, Choon-Huat Koh G. The use of salivary biomarkers in occupational and environmental medicine. Occup Environ Med 2007;64:202-10.
28. Paulsen SM, Engstad RE, Robertsen B. Enhanced lysozyme production in Atlantic salmon (Salmo salar L.) macrophages treated with yeast beta-glucan and bacterial lipopolysaccharide. Fish Shellfish Immunol 2001;11:23-37.
29. Wang YC, Chang PS, Chen HY. Differential time-series expression of immune-related genes of Pacific white shrimp Litopenaeus vannamei in response to dietary inclusion of beta-1,3-glucan. Fish Shellfish Immunol 2008;24:113-21.
30. Kirstilä V, Tenovuo J, Ruuskanen O, et al. Salivary defense factors and oral health in patients with common variable immunodeficiency. J Clin Immunol 1994;14:229-36.
31. Lehtonen OP, Tenovuo J, Aaltonen AS, et al. Immunoglobulins and innate factors of immunity in saliva of children prone to respiratory infections. Acta Pathol Microbiol Immunol Scand C 1987;95:35-40.
32. Richter J, Pelech L. Immunological findings in groups of children after compensatory measures. Toxicol Lett 1996;88:165-8.